Jeffrey Silber
Fortuna: 544 033 $ al 30/09/2026
Fortuna: 544 033 $ al 30/09/2026
Jeffrey Silber is Chief Medical Officer at Ironwood Pharmaceuticals, Inc. since 2026.
Dr. Silber was Chief Medical Officer at Vedanta Biosciences, Inc. from 2020 to 2026.
Dr. Silber completed undergraduate studies at Harvard University and earned a doctorate from Albert Einstein College of Medicine, Inc.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/07/2026 | 137.036 ( 0,08 % ) | 544 033 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 20/07/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Director Técnico/Científico/I+D | 01/07/2026 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.